GLAXO GlaxoSmithKline Pharmaceuticals Q3 FY26 results (Oct–Dec 2025) and concall
GlaxoSmithKline Pharmaceuticals reported a milestone Q3 FY26, crossing INR 1,000 crores in consolidated revenue with ~10% growth. Profitability saw significant improvement, with EBITDA margin at 35.9% and PAT margin at 27.3%. The company resolved prior supply constraints and saw strong performance in vaccines and specialty, particularly with the expanded patient pool for Jemperli in oncology. Management reiterated its ambition for 12-14% annual growth to double the business to INR 8,000 crores in the next 4-5 years, driven by new product launches and sustained base business growth.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 9.7%, net profit up 28.7% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 1,011 | 949 | 974 | 805 | 980 −3% | 1,041 +10% |
| EBITDA | 322 | 292 | 333 | 251 | 336 +4% | 371 +27% |
| Net profit | 252 | 230 | 263 | 205 | 257 +2% | 296 +29% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
